BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Sees Hot Market Potential for NanoAb Pipeline
The global dermatology pharmaceutics market is booming, with increased public awareness and large unmet needs BiondVax competitor MoonLake Immunotherapeutics share price jumped 128% after positive findings from a Phase 2 trial evaluating Nanobody(R) sonelokimab in patients with moderate-to-severe hidradenitis suppurativa, a painful long-term dermatological condition BiondVax’s NanoAbs address psoriasis and a broad range of other diseases, and with a potentially better safety profile based on administration directly into lesions, rather than MoonLake’s systemic-administration The global dermatology pharmaceutics market was valued just over $20 billion in 2022 and is expected to surge to nearly $40 billion by 2030, growing at a…
